Bio-Techne has partnered with Kantaro Biosciences, a joint venture of Mount Sinai Health System with Renalytix AI, to deliver Covid-19 antibody test kits.
The partners will develop, manufacture, sell and distribute testing kits based on the Mount Sinai-developed Covid-19 serology test.
With the step, Bio-Techne and Kantaro Biosciences aim to enable the laboratories to conduct more than ten million tests in July and further increase the capabilities in the subsequent months.
The Kantaro鈥檚 IgG antibody test kit is an enzyme-linked immunosorbent assay designed to identify the presence of anti-Covid-19 antibodies. It also measures the titer (level) of antibodies that a person has produced.
The test kit uses two virus antigens, the full-length spike protein and its receptor-binding domain, necessary for viral entry into cells.
Bio-Techne and Kantaro Biosciences have also formed a joint commercialisation and distribution team to enable rapid distribution of the assay.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBio-Techne president and CEO Chuck Kummeth said: 鈥淲e are extremely excited to partner with Kantaro and Mount Sinai to launch what we believe will be a gold standard serology test for Covid-19.
鈥淭he Bio-Techne, Mount Sinai and Kantaro teams are working around the clock to develop this test and we are on track to achieve in approximately eight weeks what would typically take 18 months or more.
鈥淎s the world leader in ELISA assays, Bio-Techne has substantial capacity and the ability to scale production levels to support much of our nation’s needs. We look forward to providing the world with critical information related to past exposure to the virus.鈥�
